1 Min Read
Sept 21 (Reuters) - Novartis AG:
* ANNOUNCES POSITIVE CHMP OPINION FOR ONE-TIME GENE THERAPY LUXTURNA® TO TREAT CHILDREN AND ADULTS WITH RARE INHERITED RETINAL DISEASE Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.